 | • レポートコード：MRC23Q36219 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、84ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の非結核性抗酸菌治療市場について調査・分析し、世界の非結核性抗酸菌治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（アジスロマイシン、リファンピン、リファブチン、エタンブト）、用途別セグメント分析（病院薬局、個人クリニック、ドラッグストア/小売薬局、電子商取引）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Insmed Incorporated、RedHill Biopharma、Novoteris、Savara、Beyond Airなどが含まれています。世界の非結核性抗酸菌治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、非結核性抗酸菌治療市場規模を推定する際に考慮しました。本レポートは、非結核性抗酸菌治療の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、非結核性抗酸菌治療に関するビジネス上の意思決定に役立てることを目的としています。 ・非結核性抗酸菌治療市場の概要 - 非結核性抗酸菌治療のタイプ別セグメント - 世界の非結核性抗酸菌治療市場規模：タイプ別分析（アジスロマイシン、リファンピン、リファブチン、エタンブト） - 非結核性抗酸菌治療の用途別セグメント - 世界の非結核性抗酸菌治療市場規模：用途別分析（病院薬局、個人クリニック、ドラッグストア/小売薬局、電子商取引） - 世界の非結核性抗酸菌治療市場規模予測（2018年-2029年） ・非結核性抗酸菌治療市場の成長トレンド - 非結核性抗酸菌治療の地域別市場規模（2018年-2029年） - 非結核性抗酸菌治療市場ダイナミクス - 非結核性抗酸菌治療の業界動向 - 非結核性抗酸菌治療市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：アジスロマイシン、リファンピン、リファブチン、エタンブト - 世界の非結核性抗酸菌治療のタイプ別市場規模（2018年-2023年） - 世界の非結核性抗酸菌治療のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院薬局、個人クリニック、ドラッグストア/小売薬局、電子商取引 - 世界の非結核性抗酸菌治療の用途別市場規模（2018年-2023年） - 世界の非結核性抗酸菌治療の用途別市場規模（2024年-2029年） ・非結核性抗酸菌治療の地域別市場規模 - 北米の非結核性抗酸菌治療市場規模（2018年-2029年） - アメリカの非結核性抗酸菌治療市場規模（2018年-2029年） - ヨーロッパの非結核性抗酸菌治療市場規模（2018年-2029年） - アジア太平洋の非結核性抗酸菌治療市場規模（2018年-2029年） - 中国の非結核性抗酸菌治療市場規模（2018年-2029年） - 日本の非結核性抗酸菌治療市場規模（2018年-2029年） - 韓国の非結核性抗酸菌治療市場規模（2018年-2029年） - インドの非結核性抗酸菌治療市場規模（2018年-2029年） - オーストラリアの非結核性抗酸菌治療市場規模（2018年-2029年） - 中南米の非結核性抗酸菌治療市場規模（2018年-2029年） - 中東・アフリカの非結核性抗酸菌治療市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Insmed Incorporated、RedHill Biopharma、Novoteris、Savara、Beyond Air ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Nontuberculous Mycobacterium Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Nontuberculous Mycobacterium Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Nontuberculous Mycobacterium Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Nontuberculous Mycobacterium Treatment in Hospitals Pharmacies is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Nontuberculous Mycobacterium Treatment include Insmed Incorporated, RedHill Biopharma, Novoteris, Savara and Beyond Air, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Nontuberculous Mycobacterium Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nontuberculous Mycobacterium Treatment.
The Nontuberculous Mycobacterium Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Nontuberculous Mycobacterium Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nontuberculous Mycobacterium Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Insmed Incorporated
RedHill Biopharma
Novoteris
Savara
Beyond Air
Segment by Type
Azithromycin
Rifampin
Rifabutin
Ethambuto
Segment by Application
Hospitals Pharmacies
Private clinics
Drug Stores and Retail Pharmacy
E-commerce
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nontuberculous Mycobacterium Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nontuberculous Mycobacterium Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Azithromycin
1.2.3 Rifampin
1.2.4 Rifabutin
1.2.5 Ethambuto
1.3 Market by Application
1.3.1 Global Nontuberculous Mycobacterium Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals Pharmacies
1.3.3 Private clinics
1.3.4 Drug Stores and Retail Pharmacy
1.3.5 E-commerce
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nontuberculous Mycobacterium Treatment Market Perspective (2018-2029)
2.2 Nontuberculous Mycobacterium Treatment Growth Trends by Region
2.2.1 Global Nontuberculous Mycobacterium Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Nontuberculous Mycobacterium Treatment Historic Market Size by Region (2018-2023)
2.2.3 Nontuberculous Mycobacterium Treatment Forecasted Market Size by Region (2024-2029)
2.3 Nontuberculous Mycobacterium Treatment Market Dynamics
2.3.1 Nontuberculous Mycobacterium Treatment Industry Trends
2.3.2 Nontuberculous Mycobacterium Treatment Market Drivers
2.3.3 Nontuberculous Mycobacterium Treatment Market Challenges
2.3.4 Nontuberculous Mycobacterium Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Nontuberculous Mycobacterium Treatment Players by Revenue
3.1.1 Global Top Nontuberculous Mycobacterium Treatment Players by Revenue (2018-2023)
3.1.2 Global Nontuberculous Mycobacterium Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Nontuberculous Mycobacterium Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Nontuberculous Mycobacterium Treatment Revenue
3.4 Global Nontuberculous Mycobacterium Treatment Market Concentration Ratio
3.4.1 Global Nontuberculous Mycobacterium Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nontuberculous Mycobacterium Treatment Revenue in 2022
3.5 Nontuberculous Mycobacterium Treatment Key Players Head office and Area Served
3.6 Key Players Nontuberculous Mycobacterium Treatment Product Solution and Service
3.7 Date of Enter into Nontuberculous Mycobacterium Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Nontuberculous Mycobacterium Treatment Breakdown Data by Type
4.1 Global Nontuberculous Mycobacterium Treatment Historic Market Size by Type (2018-2023)
4.2 Global Nontuberculous Mycobacterium Treatment Forecasted Market Size by Type (2024-2029)
5 Nontuberculous Mycobacterium Treatment Breakdown Data by Application
5.1 Global Nontuberculous Mycobacterium Treatment Historic Market Size by Application (2018-2023)
5.2 Global Nontuberculous Mycobacterium Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Nontuberculous Mycobacterium Treatment Market Size (2018-2029)
6.2 North America Nontuberculous Mycobacterium Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Nontuberculous Mycobacterium Treatment Market Size by Country (2018-2023)
6.4 North America Nontuberculous Mycobacterium Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Nontuberculous Mycobacterium Treatment Market Size (2018-2029)
7.2 Europe Nontuberculous Mycobacterium Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Nontuberculous Mycobacterium Treatment Market Size by Country (2018-2023)
7.4 Europe Nontuberculous Mycobacterium Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Nontuberculous Mycobacterium Treatment Market Size (2018-2029)
8.2 Asia-Pacific Nontuberculous Mycobacterium Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Nontuberculous Mycobacterium Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Nontuberculous Mycobacterium Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Nontuberculous Mycobacterium Treatment Market Size (2018-2029)
9.2 Latin America Nontuberculous Mycobacterium Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Nontuberculous Mycobacterium Treatment Market Size by Country (2018-2023)
9.4 Latin America Nontuberculous Mycobacterium Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Nontuberculous Mycobacterium Treatment Market Size (2018-2029)
10.2 Middle East & Africa Nontuberculous Mycobacterium Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Nontuberculous Mycobacterium Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Nontuberculous Mycobacterium Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Insmed Incorporated
11.1.1 Insmed Incorporated Company Detail
11.1.2 Insmed Incorporated Business Overview
11.1.3 Insmed Incorporated Nontuberculous Mycobacterium Treatment Introduction
11.1.4 Insmed Incorporated Revenue in Nontuberculous Mycobacterium Treatment Business (2018-2023)
11.1.5 Insmed Incorporated Recent Development
11.2 RedHill Biopharma
11.2.1 RedHill Biopharma Company Detail
11.2.2 RedHill Biopharma Business Overview
11.2.3 RedHill Biopharma Nontuberculous Mycobacterium Treatment Introduction
11.2.4 RedHill Biopharma Revenue in Nontuberculous Mycobacterium Treatment Business (2018-2023)
11.2.5 RedHill Biopharma Recent Development
11.3 Novoteris
11.3.1 Novoteris Company Detail
11.3.2 Novoteris Business Overview
11.3.3 Novoteris Nontuberculous Mycobacterium Treatment Introduction
11.3.4 Novoteris Revenue in Nontuberculous Mycobacterium Treatment Business (2018-2023)
11.3.5 Novoteris Recent Development
11.4 Savara
11.4.1 Savara Company Detail
11.4.2 Savara Business Overview
11.4.3 Savara Nontuberculous Mycobacterium Treatment Introduction
11.4.4 Savara Revenue in Nontuberculous Mycobacterium Treatment Business (2018-2023)
11.4.5 Savara Recent Development
11.5 Beyond Air
11.5.1 Beyond Air Company Detail
11.5.2 Beyond Air Business Overview
11.5.3 Beyond Air Nontuberculous Mycobacterium Treatment Introduction
11.5.4 Beyond Air Revenue in Nontuberculous Mycobacterium Treatment Business (2018-2023)
11.5.5 Beyond Air Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details